Abeona Therapeutics Inc (ABEO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Abeona Therapeutics Inc stock (ABEO) is currently trading at $4.33. Abeona Therapeutics Inc PE ratio is 3.68. Abeona Therapeutics Inc PS ratio (Price-to-Sales) is 41.44. Analyst consensus price target for ABEO is $19.57. WallStSmart rates ABEO as Sell.
- ABEO PE ratio analysis and historical PE chart
- ABEO PS ratio (Price-to-Sales) history and trend
- ABEO intrinsic value — DCF, Graham Number, EPV models
- ABEO stock price prediction 2025 2026 2027 2028 2029 2030
- ABEO fair value vs current price
- ABEO insider transactions and insider buying
- Is ABEO undervalued or overvalued?
- Abeona Therapeutics Inc financial analysis — revenue, earnings, cash flow
- ABEO Piotroski F-Score and Altman Z-Score
- ABEO analyst price target and Smart Rating
Abeona Therapeutics Inc
📊 No data available
Try selecting a different time range
ABEO Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Abeona Therapeutics Inc (ABEO)
ABEO trades at a significant discount to its Graham intrinsic value of $8.23, offering a 39% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Abeona Therapeutics Inc (ABEO) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, price/book, profit margin. Concerns around market cap and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Abeona Therapeutics Inc (ABEO) Key Strengths (4)
Every $100 of shareholder equity generates $70 in profit
Keeps $1223 of every $100 in revenue as net profit
Trading at 1.41x book value, attractively priced
69.48% held by institutions, strong professional interest
Supporting Valuation Data
Abeona Therapeutics Inc (ABEO) Areas to Watch (4)
Losing money on operations
Revenue declining -100.00%, a shrinking business
Very expensive at 41.4x annual revenue
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Abeona Therapeutics Inc (ABEO) Detailed Analysis Report
Overall Assessment
This company scores 41/100 in our Smart Analysis, earning a D grade. Out of 8 metrics analyzed, 4 register as strengths (avg 9.0/10) while 4 fall into concern territory (avg 1.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Profit Margin, Price/Book. Valuation metrics including Price/Book (1.41) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 70.10%, Profit Margin at 1223.00%.
The Bear Case
The primary concerns are Operating Margin, Revenue Growth, Price/Sales. Some valuation metrics including Price/Sales (41.44) suggest expensive pricing. Growth concerns include Revenue Growth at -100.00%, which may limit upside. Profitability pressure is visible in Operating Margin at -422.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 70.10% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at -100.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ABEO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ABEO's Price-to-Sales ratio of 41.44x trades at a deep discount to its historical average of 438.25x (30th percentile). The current valuation is 99% below its historical high of 3089.84x set in May 2008, and 14190% above its historical low of 0.29x in Jan 2007. Over the past 12 months, the PS ratio has compressed from ~693.6x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Abeona Therapeutics Inc (ABEO) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Abeona Therapeutics Inc faces headwinds with declining revenue, though profitability provides a cushion. Revenue reached 6M with 100% decline year-over-year. Profit margins are strong at 1223.0%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 70.1% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Spending 115% of revenue (7M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 100% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -19M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Abeona Therapeutics Inc.
Bottom Line
Abeona Therapeutics Inc faces challenges with declining revenue. While profitability provides a buffer, the long-term trajectory needs to improve. Watch for management's strategic response and whether the company can stabilize or pivot to new growth drivers.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Abeona Therapeutics Inc(ABEO)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for rare, life-threatening genetic diseases. The company is headquartered in New York, New York.